ClinicalTrials.gg
RecruitingNCT05219331HYCOUpdated Feb 28, 2024

Hydrocephalus Treatment on Persistent Disorder of Consciousness

An interventional study of Ventriculoperitoneal shunt in Disorder of Consciousness, sponsored by University Hospital, Toulouse. Recruiting at 2 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-02-28.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 7 months ago, but the record still lists the study as recruiting.
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Consciousness Disorders with a site in France — 11 open to participants now, 11 under way, none of them phase 3. Consciousness Disorders · France.

Planned enrollment
16th of 22
20 · median 76
Started
2022
with 2 others
No phase
19 of 27
8 open now
Primary completion
2024-04
later than 0 of 10 live
Registered
19th of 27
by date
Lead sponsor
2 of 27
University Hospital, Toulouse

Among the 27 studies in Consciousness Disorders with a site in France, this one is the 16th largest by planned enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2022, is one of 19 with no phase, reaches primary completion later than 0 of the 10 other live ones, and was the 19th registered.

Consciousness Disorders

291 studies on the registry are indexed under Consciousness Disorders; 109 are open to participants now.

Browse Consciousness Disorders studies →

Open to participants now

11 of the 27 studies in Consciousness Disorders with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 74 Consciousness Disorders studies recruiting now, 31 (42%) set no upper age limit and 24 (32%) stop at 75 or younger; 12 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Consciousness Disorders with a site in France, or all of them as a file.
02

Study summary

After acute brain injury or haemorrhagic stroke, hydrocephalus might participate to consciousness disorder. We plan to explore whether ventriculoperitoneal shunt insertion improves consciousness in patients with vegetative or minimally conscious state and hydrocephalus. Patients with acute brain injury, persistent consciousness disorder and hydrocephalus will be shunted with a detailed follow-up at 3 months combining: clinical evaluation, FluoroDésoxyGlucose positron emission tomography imaging, high density electroencephalogram, electrocardiogram Holter and sympathetic activity by microneurography.

Read the detailed description

Persistent disorder of consciousness following acute brain injury is a major public health problem. Advances in intensive care allow a growing number of patients to survive after acute brain injury. However, one third of patients in coma following acute brain injury will not recover a consciousness. To date, no specific treatment has shown its effectiveness in the cognitive recovery of those patients. Few clinical cases suggest that hydrocephalus, which is the impairment of cerebrospinal fluid circulation in the brain, may participate to prolonged disorder of consciousness. Hence treating hydrocephalus with a shunt might improve disorders of consciousness. It is possible to gauge intracranial fluid circulation, that is hydrodynamics quantification, and measure resistance to cerebrospinal fluid outflow. Demonstration of an altered hydrodynamics favours the implantation of a shunt to improve cerebrospinal fluid circulation that might modulate brain region involved in the emergence of consciousness. The study hypothesis is that shunting a patient with persistent disorder of consciousness due to acute brain injury and hydrocephalus might improve his state of consciousness. The neural processes underlying will be assessed through comparative analyses of brain metabolic and electrophysiological signatures.

03

Conditions studied

  • Disorder of Consciousness

Keywords

  • consciousness disorder
  • hydrocephalus
  • ventriculoperitoneal shunt
  • autonomic nervous system
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult, post brain injury persistent disorder of consciousness, hydrocephalus requiring ventriculo-peritoneal shunt.

Exclusion criteria

Exclusion Criteria:

  • pregnancy, no consent
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Disorder of consciousness

    Ventriculo peritoneal shunt

    Procedure: Ventriculoperitoneal shunt

Interventions

  • ProcedureVentriculoperitoneal shunt

    Treatment oh hydrocephalus

06

What researchers measure

Primary outcomes

  1. Coma Recovery Scale-revised scale

    Yield stable estimates of patient consciousness status (higher scores mean better outcome)

    Time frame: 3 months and one years after shunt insertion

Secondary outcomes

  1. 18Ffluorodeoxyglucose positron emission tomography

    18Ffluorodeoxyglucose positron emission tomography to measure brain glucose uptake across various brain region involved in consciousness

    Time frame: 3 months after shunt insertion

  2. High density electroencephalogram

    electroencephalogram-based automatic classification to apprehend brain connectivity and conscious states

    Time frame: 3 months after shunt insertion

  3. Holter electrocardiogram and blood pressure

    electrocardiogram recording and analysis and blood pressure to gauge heart rate variability

    Time frame: 3 months after shunt insertion

  4. muscle sympathetic nerve activity

    muscle sympathetic nerve activity measured by microneurography to record the electrical activity of the postganglionic sympathetic nerve from peroneal nerves in the lower limb

    Time frame: 3 months after shunt insertion

  5. catecholamines dosage

    catecholamines dosage in blood

    Time frame: 3 months after shunt insertion

07

Study locations

2 of 2 sites recruiting
  • Clinique de Verdaich
    Gaillac-Toulza, 31550, France
    Recruiting
  • Eric SCHMIDT
    Toulouse, 31059, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Apr 2024, 18 months after the start.

Of 90 non-industry interventional studies with no phase under Consciousness Disorders, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 64. This study's planned 18 months is below that.

Counting every sponsor, half of 95 studies reached it within 19 months; a quarter within 8 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Feb 2, 2022
StartActual
Sep 16, 2022
Primary completionEst.
Apr 1, 2024
CompletionEst.
Apr 1, 2025
Last update
Feb 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05219331
Responsible party
Sponsor
First posted
Feb 2, 2022
Start date
Sep 16, 2022
Primary completion
Apr 1, 2024 (estimated)
Completion
Apr 1, 2025 (estimated)
Last update
Feb 28, 2024

Study contacts

Eric SCHMIDT, MD, PhD
Contact
schmidt.e@chu-toulouse.fr
0561775606 ext. 33
Eric SCHMIDT, MD, PhD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion